-- In a post hoc analysis of patients 65 years from the positive Phase 2b Quality study, those on semaglutide placebo lost significant lean mass and had reduced stair climb power and slower stair climb time at 16 weeks,
Why Is Veru Inc. (VERU) Stock Down Today?
Updated Nov 19, 2026 6:15 PM ET · Prev Close $2.31
Session Regime & Catalyst Assessment
68% Signal ConvictionVeru Inc. Pulling Back 8.66% on 0.54x Relative Volume
Veru Inc. (VERU) is pulling back 8.66% (-$0.20) to $2.11 on 0.54x average session volume. Relative to benchmarks, VERU is lagging the S&P 500 by -6.70%. 14-day RSI stands at 44.1, keeping momentum in a bearish regime.
-- In a post hoc analysis of patients 65 years from the positive Phase 2b Quality study, those on semaglutide placebo lost significant lean mass and had reduced stair climb power and slower stair climb time at 16 weeks,
Price ($2.11) trades relative to 20-day SMA ($2.17) and 50-day SMA ($2.32).
Market & Sector Relative Strength
VERU lagging the S&P 500 by -6.70%Options Flow & Execution Desk
Unlock 1 Strike-Verified Options Setup for VERU
Our options desk modeled ATM Call Rebound / Continuation structures for the Nov 27 expiration cycle, plus live unusual contract strike sweeps and full factor sub-scores.
Recent VERU Catalyst Headlines
Verified WireMiami, Fl, Nov. 09, 2026 Globe Newswire -- Veru Inc. Nasdaq Veru , a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic diseases and oncology, today an
--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy IC50 18.2nM in daraxonrasib resistant human pancreatic cancer cell line which is a dru
Miami, Fl, Sept. 02, 2026 Globe Newswire -- Veru Inc. Nasdaq Veru , a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory disease
1–3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $2.17 (20-day SMA resistance) for directional breakout confirmation.
Technical Regime (VERU)
BEARISH MA TRENDRetail & Crowd Sentiment
BearishTrader on StockTwits expresses bullish sentiment towards $VERU, expressing optimism about recent news and potential price movement.
About Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, Entadfi, …
Get Instant VERU Catalyst Alerts
Receive an email alert when VERU triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversVERU Session & Catalyst FAQ
Why is VERU stock down today?
Veru Inc. (VERU) is pulling back 8.66% (-$0.20) to $2.11 on 0.54x average session volume. Relative to benchmarks, VERU is lagging the S&P 500 by -6.70%. 14-day RSI stands at 44.1, keeping momentum in a bearish regime.
Is VERU stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 0.54x relative volume (low participation). Our multi-factor model currently rates VERU as HOLD. Review full valuation, quality, and timing signals on the VERU Buy or Sell Decision Brief →
What is VERU's intrinsic value and expected trading range?
At $2.11, VERU's modeled 1-to-3 session range is $1.99 – $2.23, with a key inflection level at $2.17 (20-day SMA resistance). Compare current price against multi-year cash flow projections in the VERU Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for VERU?
RSI at 44.1 reflects soft below-midline momentum. VERU trades at $2.11 relative to its 20-day SMA ($2.17) and 50-day SMA ($2.32), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.